Guardant Health, Inc. (GH) Down 4.7% — Dump the Shares?

  • GH fell 4.69% to $144.59 from $151.70 the previous trading day
  • Weiss Ratings assigns D- (Sell)
  • Market cap is $20.52B

Guardant Health, Inc. (GH) is under pressure this Monday, currently trading at $144.59 on the NASDAQ —  a $7.11 decline from the prior close of $151.70. The pullback widens the gap from the stock's recent peak. GH now sits roughly 24.3% below its 52-week high of $191.05, reached on October 6, 2026, giving back a meaningful part of the autumn rally in about six weeks. Even so, the stock remains about 94% above the bottom of its 52-week range of $74.55. Shareholders who held through the full year are still well ahead, even as recent buyers absorb the losses.

Volume stands at about 394,500 shares so far, compared with a 90-day average of roughly 2.01 million. With the regular session still open, turnover is running at about a fifth of a typical full day.


Why Guardant Health, Inc. Price is Moving Lower

The most likely source of pressure is Guardant's new convertible debt, which is scheduled to settle today. On November 12, the company priced $500 million of 0% convertible senior notes due 2032. The initial conversion price is $208.95 per share, about 35% above where the stock traded on November 11. That premium is generous, but the deal still gives investors a reason to think about future share issuance and about how much outside capital the company needs. Guardant said it plans to use the proceeds to repurchase some of its 2027 notes. It also entered into capped-call transactions designed to reduce potential dilution up to a cap. Those terms soften the impact, but they do not remove the underlying concern.

The financing follows a Q3 report that drew attention to how much cash the business is consuming. On November 5, Guardant posted a non-GAAP loss of $0.29 per share, better than the $0.31 loss analysts expected. Revenue came in at $361.0 million against a $350.8 million consensus, up 36% year over year. Management raised its 2026 revenue outlook to between $1.36 billion and $1.37 billion. However, it also raised its 2026 free-cash-flow burn forecast to $205 million to $220 million, up from $195 million to $205 million. Part of that increase reflects $10 million to $15 million in delayed CMS payments, which the company now expects to collect in the first half of 2027. Pairing a higher burn estimate with a fresh $500 million debt raise keeps investors focused on cash usage rather than top-line momentum.

The decline looks specific to Guardant. Other Health Care names traded higher in the same session, with Boston Scientific (BSX) up 0.34% and Glaukos (GKOS) up 1.22%. GH's move appears to reflect investors digesting its own financing and cash-flow story rather than a broad retreat across the sector.


What is the Guardant Health, Inc. Rating - Should I Sell?

Weiss Ratings assigns GH a D- rating. The rating was upgraded on 8/15/2024. Current recommendation is Sell. Even after that upgrade, the rating sits near the bottom of the scale. Strong sales execution has not offset the persistent losses and capital needs that dominate the risk profile.

The strongest part of the profile is the Good rating on the Total Return Index. The stock has roughly doubled from its 52-week low of $74.55, and that rerating has rewarded holders despite today's pullback. The Growth Index rating of Fair is more restrained than the headline numbers might suggest. Revenue rose 36.12%, and quarterly sales climbed 7.8% sequentially, from $334.98 million in the June quarter to $360.98 million in the September quarter. That is real commercial traction for a diagnostics company. The Growth Index is not rated higher because that expansion still comes with a per-share loss of $3.68, so the top line is growing faster than any path to earnings.

Where the picture turns decisively negative is the Very Weak Efficiency Index. A profit margin of -37.92% means Guardant loses roughly 38 cents on every dollar of revenue. A forward P/E of -41.20 signals that the market expects those losses to continue for some time. The Fair rating on the Solvency Index reflects the same tension behind today's move. The balance sheet can still attract capital on favorable terms, as the 0% coupon on the 2032 notes shows. But a rising cash-burn forecast and the need to refinance 2027 debt keep solvency from being a clear strength. The Weak Volatility Index reflects a 52-week range stretching from $74.55 to $191.05, and today's financing-driven decline is another example of how sharply the stock reprices on capital-related news.

Within the Health Care sector, Guardant Health sits alongside Glaukos Corporation (GKOS, D-). It trails Baxter International Inc. (BAX, D) and Boston Scientific Corporation (BSX, D+), both of which carry somewhat better risk/reward profiles in Weiss's framework. The comparison offers little comfort, since the peer group as a whole sits in Sell territory.


About Guardant Health, Inc.

Guardant Health, Inc. (GH) is a Health Care company focused on precision oncology. Founded in 2011 and headquartered in Palo Alto, California, the company provides blood and tissue tests and related data sets in the United States and internationally. Its flagship franchise is built on liquid biopsy. The Guardant360 CDx test profiles tumor mutations from a blood draw. The Guardant360 Liquid test measures more than 740 genes and supports all guideline-recommended biomarkers. The Guardant360 Tissue test adds genomic, transcriptomic, and epigenomic insights from tumor tissue. Beyond therapy selection, the Guardant Reveal test uses circulating tumor DNA to detect cancer at the molecular level. The Shield blood test extends the platform into colorectal cancer screening for adults, a much larger addressable market than late-stage oncology testing.

The company also runs a substantial research and biopharmaceutical business. GuardantINFINITY helps drug developers understand tumor molecular profiles and immune response. GuardantOMNI covers 500 genes, including homologous recombination repair deficiency and immuno-oncology biomarkers. GuardantINFORM pairs longitudinal tumor evolution data with clinical outcomes. GuardantConnect is a software solution that links patients with actionable alterations to relevant clinical studies. The Smart Platform delivers multiomic insights from genomic, epigenomic, and RNA-based data that scale from research to the clinic. Guardant also offers development services, including companion diagnostic development and regulatory approval, clinical study setup, technology licensing, and kit fulfillment for Shield. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development.

Guardant's competitive position rests on its early lead in blood-based cancer testing and the breadth of its test menu. That menu spans screening, therapy selection, and residual disease monitoring. The data generated across these tests feeds its biopharma offerings, creating a link between clinical volume and research revenue that narrower competitors find hard to replicate. That position depends on continued reimbursement and payer adoption, and the timing of government payments directly affects how much cash the business consumes.


Investor Outlook

Guardant Health, Inc. (GH) carries a Weiss Rating of D- (Sell). The combination of a new $500 million convertible, a higher cash-burn forecast, and a deeply negative profit margin argues for caution despite 36% revenue growth. Investors should watch whether 2026 free-cash-flow burn stays within the $205 million to $220 million range and whether the delayed CMS payments arrive in the first half of 2027 as expected. They should also track whether revenue lands within the raised $1.36 billion to $1.37 billion outlook while the 2027 notes are retired. See full rankings of all D- rated Health Care stocks inside the Weiss Stock Screener.

--

This Weiss Instant News Alert was compiled by narrative data technology, our proprietary ratings models and analysis by Weiss Ratings with the intent of providing our readers with the fastest research and independent coverage. Weiss Instant News Alerts have been reviewed by a member of our editorial staff before publication. Please send any questions or comments about this story to [email protected]
Top Tech Stocks
See All »
B
AAPL NASDAQ $352.45
B
MSFT NASDAQ $508.29
B
NVDA NASDAQ $150.96
Top Consumer Staple Stocks
See All »
B
WMT NASDAQ $127.36
B
Top Financial Stocks
See All »
B
A
JPM NYSE $324.11
B
V NYSE $415.22
Top Energy Stocks
See All »
B
CVX NYSE $205.88
B
COP NYSE $134.40
Top Health Care Stocks
See All »
B
LLY NYSE $1,382.75
B
JNJ NYSE $272.70
B
ABBV NYSE $286.01
Top Real Estate Stocks
See All »
B
PLD NYSE $125.22